Back to Blog
Contour next one6/11/2023 Mattress or Bathroom products that have been put into use are NOT eligible for return. Items NOT eligible for return if the product packaging has been opened include, but are not limited to: Products classified as a "Medical Device" by the FDA (Food & Drug Administration) or manufacturer Case Pack items Contour Products (pillows, body positioners, etc.). The following products if the product has been put into use: Mattresses Mattress Pads Bath Lifts Bathroom Safety Products Bedding Products. There are certain products that are inherently Non-Returnable due to the nature of the product, sterile/hygienic concerns, or for custom-built reasons. Because many of the items offered at NewLeaf Home Medical are considered "Medical Devices," there are a few strict guidelines that need to be followed for medical compliance and hygenic reasons. Your satisfaction as our customer is our top priority, and we want you to be completely satisified with your purchase. Orders that have been paid for by credit card, debit card, or PayPal may be subject to the non-recoverable 3.5% processing fee that is assessed by the credit card company when a transaction is processed. Orders that are cancelled after they have shipped are subject to any applicable manufacturer restocking fees, return shipping and original shipping costs as outlined below. *There is no glucose data generated when the transmitter is removed.Because NewLeaf strives to deliver customer orders as quickly as possible, most orders are processed and shipped the day they are ordered. Diabetes Technology & Therapeutics, 24(2), 1-9. Evaluation of Accuracy and Safety of the NextGeneration Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. To learn more, please refer to the recent Eversense CGM Virtual Analyst and Investor Event hosted by Ascensia, Senseonics Holdings (NYSE: SENS) and PHC Holdings Corporation (TSE: 6523).ġ Garg, S. Senseonics remains responsible for research, development, innovation, and manufacturing while Ascensia is able to leverage its market-leading position in BGM to exclusively lead worldwide marketing and commercialization.Įversense CGM Systems and the Eversense CGM App are available across the US and select countries in Europe. Last year's launch was an important landmark in the global partnership between Ascensia and Senseonics, which has supported both patient access to Eversense and the development of future products, by allowing both companies to focus on their core strengths. Ongoing expansion of our dedicated CGM salesforce to help drive Eversense awareness and adoption Majority of our new users are moving from their current CGM to Eversense Increasing opportunity for people living with type 2 diabetes, with type 2 diabetes patients accounting for half of those using the system Growing number of certified inserters, supplemented by a network of certified mobile and at-home inserters through the Nurse Practitioner Group partnership Number of Eversense users significantly expanded since the launch of Eversense E3, providing a foundation for the strong growth that we expect in the US this yearĬontinuation of PASS (Payment Assistance and Simple Savings) Program to reduce out-of-pocket expenses for Eversense users with insurance coverage Significant coverage success with over 250 million covered lives, including favorable Medicare reimbursement and coverage from nearly all major national insurers Key highlights from the past year include: Alongside improved longevity, this next-generation system also offers people with diabetes unique and competitive features such as a fully implantable sensor, a removable smart transmitter*, discreet on-body vibe alerts, exceptional accuracy 1 and an intuitive smartphone app. Developed by Senseonics, the system includes the longest lasting CGM sensor available, with up to six-months of wear, compared to just one or two weeks with most CGM systems. In April 2022, Ascensia launched the Eversense ® E3 CGM System for patients in the U.S., shortly after it was approved by the U.S. Together, we have an ambitious vision for what the diabetes management of tomorrow looks like, and we are increasingly excited about what the future holds." Meanwhile, Senseonics has been focused on delivering innovation based on the feedback that we both hear from patients. "At Ascensia we've been focused on driving the uptake of this highly differentiated product, and we are encouraged to see more patients accessing its benefits. "The last year has really seen our partnership with Senseonics go from strength to strength," said Rob Schumm, President and CEO of Ascensia Diabetes Care.
0 Comments
Read More
Leave a Reply. |